FDA delays decision on Biogen's multiple sclerosis drug
March 18, 2014 at 08:33 AM EDT
March 18 (Reuters) - Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application.
